AI and Patent Strategy in Life Sciences – Part 4: Using Recurring FTO Monitoring to Mitigate Patent Risk
Part 4: How recurring freedom-to-operate monitoring may help life-science companies and investors find patent risk before it becomes litigation...
Read the full articleYou might also wanna read
Artificial Intelligence, Privilege, and Work Product: Emerging Risks in the Life Sciences Industry
As artificial intelligence (AI) use has become prevalent in nearly every stage of litigation, including pre-litigation efforts, courts and l
FTC Frames AI Output Steering as a Potential Section 5 Risk
The Federal Trade Commission’s (FTC) proposed policy statement puts a new consumer-protection frame around AI model behavior: if an AI compa
Contractual Freedom to Operate: A Surgical Approach
While a freedom-to-operate (FTO) analysis often centers on patent or trademark searches, contractual commitments can establish the practical
AI Hallucinations as Legal Defense: The Accountability Gap in Corporate AI Use
Why logs make 'The AI Did It' the perfect excuse
When Capability Meets Consequence: How Business Risk, Not Technology, Dictates AI's Real Labor Market Impact
The deployment of large language models has sparked anxieties about widespread technological unemployment, yet existing evaluations predomin
FTC Seeks Comment on AI Policy Statement
On July 1, the FTC announced a request for public comment on a proposed policy statement addressing the application of section 5 of the FTC
Comments
Sign in to join the conversation.
No comments yet. Be the first.